NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it has received a notification from Nasdaq confirming the company has regained compliance with the Minimum Bid Price Requirement under Nasdaq Marketplace Rule 5550(a)(2), closing the matter. This development ensures NeuroOne's continued listing on the Nasdaq Capital Market, providing stability for investors and maintaining the company's access to public capital markets.
The company had previously been notified by Nasdaq on May 6, 2025, that its common stock's closing bid price had fallen below the required $1 per share for 30 consecutive business days. In response, Nasdaq granted NeuroOne a 180-day extension on November 4, 2025, until May 4, 2026, to address the deficiency. To meet the requirement, NeuroOne effected a 1-for-6 reverse stock split, which became effective at 5:00 p.m. Eastern Time on April 15, 2026. The company's common stock began trading on a split-adjusted basis at the market open on April 16, 2026, under the same ticker symbol "NMTC" but with a new CUSIP number, 64130M308.
Regaining compliance is a critical milestone for NeuroOne, as it avoids potential delisting from Nasdaq, which could have negatively impacted shareholder value and the company's ability to raise capital. The reverse stock split was a strategic move to boost the stock price above the $1 threshold, demonstrating the company's commitment to maintaining its listing status. For investors, this news signals that NeuroOne has taken decisive action to address its stock price challenges, potentially restoring confidence in the company's financial health and long-term prospects.
NeuroOne is a medical technology company focused on improving surgical care for patients with neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. Additionally, NeuroOne is engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. More information is available at nmtc1.com.
The implications of this compliance restoration extend beyond NeuroOne itself. For the medical device industry, it underscores the importance of maintaining listing standards to ensure investor protection and market integrity. For NeuroOne's stakeholders, including patients and healthcare providers, the company's continued Nasdaq listing supports its ability to advance innovative neurological solutions. As NeuroOne moves forward, its focus remains on developing technologies that address unmet needs in neurological care, potentially benefiting the broader healthcare landscape.
